Loading...
Jonexa Up Intra-Articular Syringe Sodium Hyaluronate Cross-Linked 2% 4.4 Ml Abiogen
€168,27
Unit price
/
Unavailable
Tax included, shipping and discounts calculated at checkout.
ABIOGEN PHARMA | SKU:
989021011
Jonexa Up Intra-Articular Syringe Sodium Hyaluronate Cross-Linked 2% 4.4 Ml Abiogen is backordered and will ship as soon as it is back in stock.
Shipping Costs and Times
Shipping Costs and Times
- Order fulfillment within 24 hours and delivery within the following 48/72 hours.
- Shipping cost: always free for orders over €49.90, otherwise it costs €4.99.
Payments
Payments
Payment information is processed securely. We do not store credit card information or have access to your credit card information.
Returns and Refunds
Returns and Refunds
You can return and receive a refund for the item within 30 days. See full policy here.
Jonexa Up Intra-Articular Syringe Sodium Hyaluronate Cross-Linked 2...
€168,27
Unit price
/
Unavailable
Do you need help?
Our customer service is here to help you!
- Contact us by phone, email or WhatsApp, from Monday to Friday, from 9:00 to 20:00 .
- For common questions, such as tracking your order or checking its fulfillment status, you can count on our artificial intelligence , available 24/7 .
We are always at your side to offer you fast and effective support!
Description
Description
JONEXA UP INTRA-ARTICULAR SYRINGE SODIUM HYALURONATE CROSS-LINKED 2% 4.4 ML ABIOGEN
Jonexa UP
Description
Biocompatible hydrogel of cross-linked sodium hyaluronate obtained by biofermentation and highly purified, dissolved in a physiological and isotonic buffer. The product is an injectable, sterile and apyrogenic hydrogel, with a low level of endotoxins.
JONEXA UP is formulated with highly purified sodium hyaluronate, quality salts compliant with the requirements reported in the Pharmacopoeia and water for injections.
JONEXA UP reduces pain and increases the functionality of the affected joint.
JONEXA UP provides a lubricating and shock-absorbing effect on the affected joint.
JONEXA UP improves the patient's quality of life.
JONEXA UP must be administered by intra-articular injection by a qualified physician following all rules regarding aseptic procedure and injection technique.
JONEXA UP must be injected with a suitable sterile needle (18-21G needles are recommended).
It is recommended that JONEXA UP be administered in a single session. The amount of product to be administered is at the discretion of the medical specialist. Discard any unused portion of the syringe.
How to use
JONEXA UP should be injected into the joint into the synovial space of the knee, as a means of viscosupplementation for the synovial fluid, when the viscosity of the fluid is reduced due to the osteoarthritis process, in patients who have not responded adequately to conservative non-pharmacological therapy and simple analgesics.
1. Before the injection, the area to be treated must be thoroughly disinfected and the product must be brought to room temperature.
2. Open the sterile packaging and remove the syringe from inside.
3. Remove the cap from the tip of the syringe without touching it, to keep it sterile.
4. Attach a suitable sterile needle (18-21G needles are recommended) to the tip of the syringe.
Make sure the needle is properly locked onto the syringe's Luer-lock adapter before using it.
5. Remove air from the syringe, if necessary.
6. Inject into the joint into the synovial space of the affected knee, following aseptic injection procedures.
7. At the end of the treatment session, throw away the syringe and any remaining product.
The amount of product to be administered is at the discretion of the specialist doctor, the recommended dose is 3-4 ml for each knee joint.
Components
Cross-linked sodium hyaluronate 20 mg/ml, disodium phosphate dodecahydrate 0.6 mg/ml, sodium dihydrogen phosphate dihydrate 0.05 mg/ml, sodium chloride 8 mg/ml, water for injections qs
Warnings
Do not administer JONEXA UP to patients with known hypersensitivity (allergy) to hyaluronic acid and/or other components of the product.
Do not administer JONEXA UP to patients with acute or chronic dermatological disorders or with inflammatory and/or infectious skin problems.
Do not administer JONEXA UP to patients with coagulation disorders and/or undergoing treatment with anticoagulant drugs.
JONEXA UP should not be administered to women who are pregnant or breastfeeding.
JONEXA UP should not be administered to children.
The use of JONEXA UP in any joint other than the knee and for other conditions has not been studied.
JONEXA UP must be strictly injected into the intra-articular space following aseptic injection procedures.
JONEXA UP must be administered with sterile Luer-lock needles.
Do not inject into a blood vessel or surrounding tissue. To avoid pain after the injection, it is recommended to keep the local injection site still.
The product should not be used if the packaging is damaged or broken.
The product should not be used after the expiry date.
The product is for single use only. Do not reuse; risk of infection.
Do not resterilize, resterilization may affect the physical-chemical properties of the product and compromise its efficacy and safety.
The used syringe and needle must be thrown into a special container.
Keep out of reach of children.
Do not use with other products containing quaternary ammonium salts such as benzalkonium chloride or with any surgical material treated with these types of substances, as sodium hyaluronate may precipitate in their presence. In order to prevent any possible interaction, avoid co-administration with other intra-articular products.
No interactions with other local anesthetics are known.
Conservation
Store between 5°C and 25°C. Protect from light and avoid freezing.
Do not use after the date shown on the package.
Format
4.4 ml syringe.
Code 6801
Biocompatible hydrogel of cross-linked sodium hyaluronate obtained by biofermentation and highly purified, dissolved in a physiological and isotonic buffer. The product is an injectable, sterile and apyrogenic hydrogel, with a low level of endotoxins.
JONEXA UP is formulated with highly purified sodium hyaluronate, quality salts compliant with the requirements reported in the Pharmacopoeia and water for injections.
JONEXA UP reduces pain and increases the functionality of the affected joint.
JONEXA UP provides a lubricating and shock-absorbing effect on the affected joint.
JONEXA UP improves the patient's quality of life.
JONEXA UP must be administered by intra-articular injection by a qualified physician following all rules regarding aseptic procedure and injection technique.
JONEXA UP must be injected with a suitable sterile needle (18-21G needles are recommended).
It is recommended that JONEXA UP be administered in a single session. The amount of product to be administered is at the discretion of the medical specialist. Discard any unused portion of the syringe.
How to use
JONEXA UP should be injected into the joint into the synovial space of the knee, as a means of viscosupplementation for the synovial fluid, when the viscosity of the fluid is reduced due to the osteoarthritis process, in patients who have not responded adequately to conservative non-pharmacological therapy and simple analgesics.
1. Before the injection, the area to be treated must be thoroughly disinfected and the product must be brought to room temperature.
2. Open the sterile packaging and remove the syringe from inside.
3. Remove the cap from the tip of the syringe without touching it, to keep it sterile.
4. Attach a suitable sterile needle (18-21G needles are recommended) to the tip of the syringe.
Make sure the needle is properly locked onto the syringe's Luer-lock adapter before using it.
5. Remove air from the syringe, if necessary.
6. Inject into the joint into the synovial space of the affected knee, following aseptic injection procedures.
7. At the end of the treatment session, throw away the syringe and any remaining product.
The amount of product to be administered is at the discretion of the specialist doctor, the recommended dose is 3-4 ml for each knee joint.
Components
Cross-linked sodium hyaluronate 20 mg/ml, disodium phosphate dodecahydrate 0.6 mg/ml, sodium dihydrogen phosphate dihydrate 0.05 mg/ml, sodium chloride 8 mg/ml, water for injections qs
Warnings
Do not administer JONEXA UP to patients with known hypersensitivity (allergy) to hyaluronic acid and/or other components of the product.
Do not administer JONEXA UP to patients with acute or chronic dermatological disorders or with inflammatory and/or infectious skin problems.
Do not administer JONEXA UP to patients with coagulation disorders and/or undergoing treatment with anticoagulant drugs.
JONEXA UP should not be administered to women who are pregnant or breastfeeding.
JONEXA UP should not be administered to children.
The use of JONEXA UP in any joint other than the knee and for other conditions has not been studied.
JONEXA UP must be strictly injected into the intra-articular space following aseptic injection procedures.
JONEXA UP must be administered with sterile Luer-lock needles.
Do not inject into a blood vessel or surrounding tissue. To avoid pain after the injection, it is recommended to keep the local injection site still.
The product should not be used if the packaging is damaged or broken.
The product should not be used after the expiry date.
The product is for single use only. Do not reuse; risk of infection.
Do not resterilize, resterilization may affect the physical-chemical properties of the product and compromise its efficacy and safety.
The used syringe and needle must be thrown into a special container.
Keep out of reach of children.
Do not use with other products containing quaternary ammonium salts such as benzalkonium chloride or with any surgical material treated with these types of substances, as sodium hyaluronate may precipitate in their presence. In order to prevent any possible interaction, avoid co-administration with other intra-articular products.
No interactions with other local anesthetics are known.
Conservation
Store between 5°C and 25°C. Protect from light and avoid freezing.
Do not use after the date shown on the package.
Format
4.4 ml syringe.
Code 6801